Efficacy of minimally invasive therapies on unresectable pancreatic cancer
查看参考文献22篇
|
文摘
|
For patients with unresectable pancreatic cancer, current chemotherapies have negligible survival benefits. Thus, developing effective minimally invasive therapies is currently underway. This study was conducted to evaluate the efficacy of transarterial chemoembolization plus radiofrequency ablation and/or ~(125)I radioactive seed implantation on unresectable pancreatic cancer. We analyzed the outcome of 71 patients with unresectable pancreatic carcinoma who underwent chemoembolization plus radiofrequency ablation and/or radioactive seed implantation. Of the 71 patients, the median survival was 11 months, and the 1-, 2-, and 3-year overall survival rates were 32.4%, 9.9%, and 6.6%, respectively. Patients who had no metastasis, who had oligonodular liver metastases (≤3 lesions), and who had multinodular liver metastases (>3 lesions) had median survival of 12, 18, and 8 months, respectively, and 1-year overall survival rates of 50.0%, 68.8%, and 5.7%, respectively. Although the survival of patients without liver metastases was worse than that of patients with oligonodular liver metastasis, the result was not significant (P = 0.239). In contrast, the metastasis-negative patients had significantly better survival than did patients with multinodular liver metastases (P < 0.001). Patients with oligonodular liver lesions had a significanthg longer median survival than did patients with multinodular lesions (P < 0.001). In conclusion, combined minimally invasive therapies had good efficacy on unresectable pancreatic cancer and resulted in a good control of liver metastases. In addition, the number of liver metastases was a significant factor in predicting prognosis and response to treatment. |
|
来源
|
Chinese Journal of Cancer
,2013,32(6):334-341 【核心库】
|
|
关键词
|
Pancreatic cancer
;
minimally invasive therapies
;
transarterial chemoembolization
;
radiofrequency ablation
;
median survival
|
|
地址
|
1.
Division of Medical Imaging and Interventional Radiology, Sun Yat-sen University Cancer Center, State Key Loboratory of Oncology in South China, Guangdong, Guangzhou, 510060
2.
Medical Oncology, Sichuan Cancer Hospital & Institute, The Second People's Hospital of Sichuan Province, Sichuan, Chengdu, 610041
3.
Undergraduate College, The University of Chicago, USA, Chicago, 60615
|
|
语种
|
英文 |
|
文献类型
|
研究性论文 |
|
ISSN
|
1000-467X |
|
学科
|
肿瘤学 |
|
文献收藏号
|
CSCD:4870551
|
参考文献 共
22
共2页
|
|
1.
Pantano F. MUC2 but not MUC5 expression correlates with prognosis in radically resected pancreatic cancer patients.
Cancer Biol Ther,2009,8:996-999
|
被引
2
次
|
|
|
|
|
2.
Hart A R. Pancreatic cancer: a review of the evidence on causation.
Clin Gastroenterol Hepatol,2008,6:275-282
|
被引
4
次
|
|
|
|
|
3.
Tempero M. Pancreatic adenocarcinoma. Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw,2007,5:998-1033
|
被引
3
次
|
|
|
|
|
4.
Fryer R A. Recent advances and developments in treatment strategies against pancreatic cancer.
Curr Clin Pharmacol,2009,4:102-112
|
被引
9
次
|
|
|
|
|
5.
Vogl T J. Transarterial chemo-perfusion with gemcitabine and mitomycin c in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages.
Rofo,2007,179:1181-1188
|
被引
1
次
|
|
|
|
|
6.
Khajanchee Y S. Hepatic resection vs minimally invasive radiofrequency ablation for the treatment of colorectal liver metastases: a Markov analysis.
Arch Surg,2011,146:1416-1423
|
被引
3
次
|
|
|
|
|
7.
Jin Y. Radiofrequency ablation combined with systemic chemotherapy in nasopharyngeal carcinoma liver metastases improves response to treatment and survival outcomes.
J Surg Oncol,2012,106:322-326
|
被引
11
次
|
|
|
|
|
8.
Wu P H. Percutaneous radiofrequency ablation approach through the spleen:initial case report for pancreatic tail gastrinoma.
Chin J Cancer,2010,29:836-841
|
被引
1
次
|
|
|
|
|
9.
Zhang F J. CT guided radioactive seed ~125l implantation in treatment of pancreatic cancer.
Zhonghua Yi Xue Za Zhi. [in Chinese],2006,86:223-227
|
被引
1
次
|
|
|
|
|
10.
Park J O. Measuring response in solid tumors: comparison of RECIST and WHO response criteria.
Jpn J Clin Oncol,2003,33:533-537
|
被引
13
次
|
|
|
|
|
11.
Pan C. Subdividing the M1 stage of liver metastasis for nasopharyngeal carcinoma to better predict metastatic survival.
Med Oncol,2011,28:1349-1355
|
被引
11
次
|
|
|
|
|
12.
.
Statistics USC. Surveillance epidemiology and end results (SEER). 1999-2007 incidence and mortality report,2011
|
被引
1
次
|
|
|
|
|
13.
Vogl T J. Liver metastases of neuroendocrine tumors: treatment with hepatic transarterial chemotherapy using two therapeutic protocols.
AJR Am J Roentgenol,2009,193:941-947
|
被引
4
次
|
|
|
|
|
14.
Heinemann V. Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer.
BMC Cancer,2008,8:82
|
被引
20
次
|
|
|
|
|
15.
Saif M W. New developments in the treatment of pancreatic cancer.
Highlights from the "44th ASCO Annual Meeting". Chicago, IL, USA. May 30-June 3, 2008. 9,2008:391-397
|
被引
1
次
|
|
|
|
|
16.
Campen C J. Management strategies in pancreatic cancer.
Am J Health Syst Pharm,2011,68:573-584
|
被引
2
次
|
|
|
|
|
17.
Wang L Q. Influence of dearterialization on distribution of absolute tumor blood flow between hepatic artery and portal vein.
Cancer,1994,74:2454-2459
|
被引
3
次
|
|
|
|
|
18.
Varadhachary G R. Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy.
Ann Surg Oncol,2006,13:1035-1046
|
被引
47
次
|
|
|
|
|
19.
Kelley R K. Erlotinib in the treatment of advanced pancreatic cancer.
Biologics,2008,2:83-95
|
被引
2
次
|
|
|
|
|
20.
Moureau-Zabotto L. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
J Clin Oncol,2008,26:1080-1085
|
被引
2
次
|
|
|
|
|
了解气象卫星更多信息，请访问